jRCT2080222628已完成3 期
A Phase 3 Study of CS-8958 (Prophylaxis of Single Administration) - A randomized, double-blind, placebo-controlled study to evaluate the efficacy of single dose administration for the prevention of influenza virus infection -
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 750
- 试验地点
- 1
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Multicenter, randomized, double-blind, 3-parallel-group, placebo-controlled
- 主要目的
- Prevention Purpose
入排标准
- 年龄范围
- 10age old over 至 No limit（—）
- 性别
- All
入选标准
- •Household contact of a patient with influenza virus infection
- •Body temperature (axillary) at informed consent =< 36.9 degrees C
- •No influenza symptoms
排除标准
- •Persons who are unable to cohabit with an index patient
- •Persons who cannot start study treatment within 48 hours after the initial onset of any influenza symptom in the index patient
- •Persons receiving corticosteroids or immunosuppressants
- •Persons who have a history of hypersensitivity to a neuraminidase inhibitor
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A Phase 3 Study of nebulized CS-8958 (Treatment of influenza)jRCT2080223342DAIICHI SANKYO Co.,Ltd.500
已完成
3 期
A Phase 3 Study of CS-8958 (Prophylaxis of Single Administration)JPRN-jRCT2080222628DAIICHI SANKYO CO., LTD.803
未知
3 期
CS-747S PhaseIII trial (elective PCI)JPRN-jRCT2080221511DAIICHISANKYO Co.,Ltd.600
已完成
3 期
A Phase 3 Study of nebulized CS-8958 (Pediatric Patients < 10 years of age)jRCT2080223343DAIICHI SANKYO Co.,Ltd.150
未知
3 期
Add-on, open-label, phase III study of CS-866AZEssential hypertensionJPRN-jRCT2080220290DAIICHISANKYO Co.,Ltd.